179 related articles for article (PubMed ID: 9220287)
21. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin.
Drees M; Dengler WM; Hendriks HR; Kelland LR; Fiebig HH
Eur J Cancer; 1995; 31A(3):356-61. PubMed ID: 7786602
[TBL] [Abstract][Full Text] [Related]
22. Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy.
Kollmannsberger C; Mayer F; Kuczyk M; Kanz L; Bokemeyer C
World J Urol; 2001 Apr; 19(2):120-5. PubMed ID: 11374314
[TBL] [Abstract][Full Text] [Related]
23. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
[TBL] [Abstract][Full Text] [Related]
24. Ifosfamide in the treatment of germ cell tumors.
Nichols CR
Semin Oncol; 1996 Jun; 23(3 Suppl 6):65-73. PubMed ID: 8677452
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
[TBL] [Abstract][Full Text] [Related]
26. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
27. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
28. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.
Nicoletti MI; Lucchini V; Massazza G; Abbott BJ; D'Incalci M; Giavazzi R
Ann Oncol; 1993 Feb; 4(2):151-5. PubMed ID: 8095399
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts.
Yamori T; Sato S; Chikazawa H; Kadota T
Jpn J Cancer Res; 1997 Dec; 88(12):1205-10. PubMed ID: 9473739
[TBL] [Abstract][Full Text] [Related]
31. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel (Taxol) combination therapy for resistant germ cell tumors.
Motzer RJ
Semin Oncol; 2000 Feb; 27(1 Suppl 1):33-5. PubMed ID: 10697042
[TBL] [Abstract][Full Text] [Related]
34. Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression.
Peng X; Li W; Tan G
Anticancer Drugs; 2010 Apr; 21(4):381-8. PubMed ID: 20051827
[TBL] [Abstract][Full Text] [Related]
35. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
36. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer.
Kollmannsberger C; Gerl A; Schleucher N; Beyer J; Kuczyk M; Rick O; Casper J; Sosada M; Rie C; Kanz L; Bokemeyer C
Anticancer Drugs; 2000 Aug; 11(7):535-9. PubMed ID: 11036955
[TBL] [Abstract][Full Text] [Related]
38. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
39. Studies on drug resistance in a human melanoma xenograft system.
Osieka R
Cancer Treat Rev; 1984 Mar; 11 Suppl A():85-98. PubMed ID: 6539651
[TBL] [Abstract][Full Text] [Related]
40. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
